Board of Directors
Dr. Michael Raymont
Dr. Raymont’s career has spanned leadership roles in venture capital, agricultural and healthcare investment, tech company leadership and senior Government service, where he ran the National Research Council (NRC), Canada’s largest R&D organization. With a background in both science and business, Dr. Raymont has advised corporations and governments, worked extensively internationally, and has sat on the boards of over 50 public and private companies.
Public Company Management and Accounting Professional including Financial, Disclosure and Compliance Responsibilities in the medical cannabis, agriculture, biotech, nutraceuticals, real estate development and business software systems industries with 20+ years of experience. Past experience includes Director and CEO of Grand Peak Capital Corp., a publicly listed Venture Capital Corp investing in portfolio of Resource and Technology Companies. Comprehensive understanding of the new technology and IP development with close relationships federal and provincial government funding agencies.
Founding partner at The Conscious Fund, one of the most active venture funds in psychedelic medicine. Richard serves as the Chair of MicroDose the leading media company for the business of psychedelics and as a board member of Hive Bio and an advisor to the Psychedelic Medicine Association. Previous experience includes the co-founder of the FinTech Pollen VC and the multimillion downloaded app from mental health startup Digipill.
Frank has helped leading companies and brands in emerging industries thrive in the capital and consumer markets through innovative digital marketing strategies and services. He founded CFN Media in 2013 and grew the company to become the leading financial media network serving the global cannabis, CBD and psychedelics markets. CFN Media is now CFN Enterprises trading on the QTCQB. Frank has spent the previous 15+ years disrupting financial media by scaling new platforms and services that drive revenue and grown.
25+ years of public practice and company management advising corporations and their executives on financing, mergers and acquisitions, going public transaction, continuous disclosure obligations, and corporate governance. Rob spent 15 years as the Director of Listings for the TSX Venture Exchange. Rob also has extensive knowledge and expertise in Venture Exchange practices, policies, regulatory compliance and risk mitigation.
Chief Medical Officer
Dr Malcolm Barratt-Johnson
Malcolm has over 22 years in the pharmaceutical industry specialising in Medical Affairs, Product Development and Regulatory Strategy. Malcolm has worked extensively in senior positions to both Industry and Government. Holding positions at AstraZeneca, Roche, and the UK Medicines Regulatory Agency (MHRA) and European Medicines Evaluation Agency (EMEA). More recently Malcolm, as a Clinical Specialist chaired the European Commission’s Biomedical Research Programme (Horizon 2020). He has also lectured in both Europe and the United States on Medicine & Drug Development.
Chief Commercial Officer
30+ years in the pharmaceutical industry holding senior management positions in Astra Zeneca, GlaxoSmithKline and Bristol Myers before starting two B2B companies specializing in Pharma Market Access, having brought in excess of 60 products to market in key areas of mental, cancer, and other national agenda diseases. A keen entrepreneur, Graeme enjoys growing start-up companies and has a special interest in new technologies that advance the improvement of healthcare delivery, unmet need and patient centred solutions.
Chief Development Officer
Ali has 15+ years engineering experience in the development and commercialization of novel process technologies in oil and gas, pulp and paper, electrochemistry and pharmaceutical sectors. In 2011, Ali founded AGEIAS Engineered Systems Ltd., an EPCM focused on the design and build of modular systems for proof of concept, demonstration, and commercial prototypes servicing clients from academic institutions, contract research organizations and laboratories. Ali has extensive experience in the management of both short term and longer multi-year R&D programs programs with a track record of commercialization.
Chief Communications Officer
Barney is a product & marketing entrepreneur in residence with the Conscious Fund. One of the most active venture funds in psychedelic medicine. Barney is also one of the founders of the Psychedelic Medicine Association where he serves as Chief Technical Officer. The Psychedelic Medicine Association is aimed at bridging the gap between the advances taking place in the psychedelic research world and medical practitioners. Prior to his work in the psychedelic industry Barney founded Noid Drinks a cannabinoid beverage company from the UK. Barney also holds a Masters degree in Engineering.
25+ years experience in executive and operational management, marketing, brand building, and retail distribution in the European cosmetic and pharmaceutical markets with Pharma giants such as Novartis and Bristol Myers. Recently, Santoke was the Managing Director for Pierre Fabre UK, the global botanical extracts specialist. Pierre Fabre comprises a range of dermocosmetics with leading brands, as well as an extensive range in healthcare and prescription medicines.
Dr. Shabir Hasham
Dr Hasham has more than 15 years’ experience in the biotechnology sector spanning clinical development and commercialisation of novel therapies. He has led teams in the design and execution of clinical trials, interactions with Regulatory Authorities and Regulatory submissions to both the FDA and EMEA as well as having launched multiple blockbusters during his tenure with Pfizer, Biogen Idec and Novartis.
Standing on the shoulders of the giants that went before.
We are driven to develop the vision of those that revealed the true power of psychedelics as medicines.
Let us tell you more.
We will email you to start the conversation.